Related Experiment Video
Updated: Feb 25, 2026

Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
Published on: March 24, 2023
[NON-ARTHROPLASTY TREATMENT FOR KNEE OSTEOARTHRITIS]
Ido Stahl1, Eyal Ginesin1, Nir Hous1
1Orthopedic Surgery Division - Rambam Health Care Campus.
Introduction:
Osteoarthritis is characterized by marked pain, stiffness and reduced range of motion and is one of the most common causes of disability and reduced quality of life. The disease is diagnosed in 20% of the adult population; the prevalence rises to 50% of adults over 65 years of age. There are various treatment options in the early stages of knee osteoarthritis which are intended to postpone the need for arthroplasty, which is the gold standard treatment at the end-stage level of the disease. Evidence based medicine (EBM) facilitates optimized decision-making and treatment for an individual patient based on meta-analysis, randomize control studies and systematic reviews. Based on these studies, physical activity is an effective treatment option resulting in reduced disability and improved quality of life. Among other conservative treatment options, chondroitin, a food supplement, was found to be as effective as anti-inflammatory medication with a lower side effect profile. Similar results were found for intra-articular injections of hyaluronic acid, while intra-articular injections of platelet rich plasma (PRP) were found to be the most effective of all the above. No advantage was reported for knee arthroscopy over conservative treatment options even when examining those patients with combined symptomatic meniscal tear and knee osteoarthritis. Non-steroidal anti-inflammatory medication (NSAIDS) and opiate treatment have limited long term effect on reducing pain, disability and improving quality of life. These drugs can have a high rate of substantial side effect. Hence, their use should be limited, especially in the elderly population, and safer modalities should be explored.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease III: Interprofessional Care
Rheumatic Heart Disease III: Medical Management

